Urinary Tract Infection (UTI) for LTCF Page 1 of 4 OMB No. xxxx-xxxx Exp. Date: xx-xx-xxxx * required for saving *Facility ID: Event #: *Resident ID:*Social.

Slides:



Advertisements
Similar presentations
PART II CATHETER RELATED BLOOD STREAM INFECTION (CR-BSI) CATHETER RELATED URINARY TRACT INFECTIN (CR-UTI)
Advertisements

TREATMENT FOR SUPERIMPOSED PSEUDOMONAS AERUGINOSA INFECTION.
Facility ID:________________Event#_________________________ *Patient ID:_____________________ Social Security#: __ __ __ - __ __ - __ __ __ __ Secondary.
Introduction to the National Healthcare Safety Network (NHSN) Richard Rodriguez, MPH Connecticut Department of Public Health 4/9/2014 Thank you to CDC.
James Marx, PhD, RN, CIC Broad Street Solutions October 2014.
URINARY TRACT INFECTION
HAI Surveillance & Definitions In LTCF
MANUAL on ALERT ORGANISM SURVEILLANCE
Sorting Out Antibiotics: A systematic approach to antibiotic selection Kenneth Alexander, M.D., Ph.D. Associate Professor of Pediatrics and Microbiology.
Catheter-Associated Urinary Tract Infections
BAD BUGS! Alfred DeMaria, Jr., M.D. Massachusetts Department of Public Health.
PROSTATE INFECTION Acute Bacterial Prostatitis
Gram Negative Gram Positive
Culture and Sensitivity Helping the Infection Preventionist Interpret Antibiograms Walter Phillips, BS, MS, PhD Director of Microbiology TriStar Healthcare.
Facility ID#: *HCW ID#:Social Security #: Secondary ID#: HCW Name, Last: First: Middle: Street Address: City:State:Zip Code: Home Phone: ( ) Address:
MDR Organisms in Holy Family Hospital Rawalpindi
Using Nursing Home Antibiograms To Improve Antibiotic Prescribing and Delivery Training Slides for Prescribing Clinicians Comprehensive Antibiogram Toolkit.
INF 1 ® Life-Threatening Infections INF 1 ®. INF 2 ® Objectives Recognize predisposing conditions for infection Identify clinical manifestations of infection.
Custom Event Page 1 of 4 * required for saving Facility ID: Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender:
Urinalysis and UTIs: Improving Care
NHSN N ATIONAL H EALTHCARE S AFETY N ETWORK Catheter-Associated Urinary Tract Infection (CAUTI) ELSA SANTOS-CRUZ, CIC MOUNT SINAI MEDICAL CENTER (INFECTION.
Facility ID: Vaccination #: Healthcare Worker Demographics *HCW ID#: HCW Name, Last:First:Middle: *Gender:  F  M *Date of Birth: *Work Location: *Occupation:
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training.
Piloting HAI Data Collection in Maryland Long Term Care Facilities: Successes and Challenges Elisabeth Vaeth, MPH Epidemiologist, Emerging Infections Program.
Antimicrobial Resistance patterns among nosocomial gram negative bacilli by E-test and disc diffusion methods in Sina and Imam Hospital.
THE UTI MODULE LECTURE. To outline the aims of the UTI module To describe the questionnaires LECTURE OBJECTIVES.
© 2009 CSTS: The Cardiovascular Surgical Translational Study Using the Centers for Disease Control and Prevention’s National Healthcare Safety Network.
김의종(집필대표), 강정옥, 김미나, 김민중, 김성일, 이경원, 이도현, 이장호, 이남용, 이창규, 신종희, 장철훈, 최혜심
Common ID Syndromes March 2014.
Figure 1 shows the 10 most frequently isolated blood pathogens in these hospitals from 1997 through These species represent about 85% of blood isolates.
Antibiotics 101 A review of common infections and their treatment For others, like me, who have a mental block against all things related to antibiotics.
Onboarding Webinar #2 for LTC Facility Team Leads and Core Team
Applying the NHSN CAUTI Criteria to Case Studies
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
Catheter-associated Urinary Tract Infection (CAUTI) Criteria for defining CAUTI in long-term care residents: One or more of the following: □Fever* □Rigors.
One or more of the following, with no alternate source: □Fever* □Rigors (shaking chills) □New onset hypotension □New onset confusion/functional decline.
National Content Series for All Staff
Onboarding #2 for All Long-Term Care Staff
Onboarding Webinar #2 for LTC Facility Team Leads and Core Team
REDUCING CATHETER ASSOCIATED URINARY TRACT INFECTIONS CLINICAL EXCELLENCE COMMISSION 2015 URINE COLLECTION, CULTURE and CATHETERISATION IN ACUTE SETTINGS.
Infection Prevention: Recognizing and Communicating CAUTI
Overcoming Challenges to Reduce CAUTI and Improve Safety Culture
EARS-Net data on Antimicrobial Resistance in Ireland, Q3 2015
Center for Drug Evaluation and Research March 6, 2005 Bacteremia and Endocarditis: Products and Guidance Janice Soreth, MD Director Division of Anti-Infective.
Facility ID:Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M*Date of Birth: Ethnicity (specify):Race.
Guideline for the Diagnosis and Management of Adults in LTC with Urinary Tract Infection (Part 2) This is intended as a guide for evidence-based decision-making.
*Facility ID # : __________*Event # : __________ *Patient ID # : _____________ Social Security # : ___ ___ ___ - ___ ___ - ___ ___ ___ ___ Secondary ID.
*Facility ID:*Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M*Date of Birth: Ethnicity (specify):Race.
* required for saving Tracking #: Facility ID:*Survey Year: Facility Characteristics *Ownership (check one): □ For profit □ Not for profit, including church.
*Facility ID # : _____________ *HCW ID # : _____________ Social Security # : ___ ___ ___ - ___ ___ - ___ ___ ___ ___ Secondary ID # : _____________ HCW.
Purposes of NHSN Participation in the NHSN reflects the individual facility’s need for high quality and timely data on adverse events and adherence to.
National Hospital Care Survey (NHCS). 2 Overview What is the National Center for Health Statistics (NCHS)? What is the National Hospital Care Survey (NHCS)?
Facility ID#: Med Admin#: Healthcare Worker Demographics *HCW ID#: *HCW Name, Last:First:Middle: *Gender:  F  M  Other *Date of Birth:// *Work Location:*Occupation:
Poster produced by Faculty & Curriculum Support (FACS), Georgetown University School of Medicine Resistance (%)Antibiotic P value Non E coli spp ** n=43(19%)
Using Nursing Home Antibiograms To Improve Antibiotic Prescribing and Delivery Training Slides for Nursing Home Nurses Comprehensive Antibiogram Toolkit.
Assurance of Confidentiality: The information obtained in this surveillance system that would permit identification of any individual or institution is.
National Hospital Care Survey (NHCS) Acute Coronary Syndrome Study.
Thank you very much for including the HD*Calc software ( on your website or social media platform. The National Cancer Institute.
*Facility ID:*Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M Other *Date of Birth: Ethnicity (specify):Race.
Facility ID:Procedure #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M*Date of Birth: Ethnicity (specify):Race.
Facility Information: *Facility Name: __________________________________________________________________ *Main Telephone Number: ( ) ______-____________.
Urinalysis in the Elderly
Reference Article.
Afaq R. Afridi, Tanveer Ahmad, Arshad Hussain and Abdul Samad.
The Role of the Microbiology Laboratory in AMS programs
Older Residents (>65) with Suspected UTI (Urinary Tract Infection)
Robin Nettleton MSN RN St. Luke’s Elmore, Mountain Home
Urinary Tract Infection and Asymptomatic Bacteriuria in Older Adults
UTI Toolkit – Module 3 When to Test a Urine Specimen?
Presentation transcript:

Urinary Tract Infection (UTI) for LTCF Page 1 of 4 OMB No. xxxx-xxxx Exp. Date: xx-xx-xxxx * required for saving *Facility ID: Event #: *Resident ID:*Social Security #: Medicare number (or comparable railroad insurance number): Resident Name, Last: First: Middle: *Gender: F M Other*Date of Birth: *Resident type: Short-stay ( 90 days) *Date of Original Admission to Facility: ___/___/_____ Ethnicity (specify):Race (specify): *Event Type: UTI*Date of Event: *MDRO Infection Surveillance: □ Yes, this infection’s pathogen & location are in-plan for Infection Surveillance in the MDRO/CDI Module □ No, this infection’s pathogen & location are not in-plan for Infection Surveillance in the MDRO/CDI Module *Resident Care Location: *Primary Resident Service Type: (Check one)  Long-term general nursing  Long-term dementia  Long-term psychiatric  Skilled nursing/Short-term rehab (subacute)  Ventilator  Bariatric  Other *Has resident been transferred from an acute care facility in the past 3 months? Yes No If Yes, date of last transfer from acute care to your facility: ___/___/_____ *Urinary Catheter status at time of specimen collection:  In place  Removed within 48 hours prior  Not in place nor within 48 hours prior *Site where Device Inserted (Check one):  Your facility  Acute care  Other facility  Clinic/community *Device Type:  Indwelling/Suprapubic  Condom (males only) Date of Device Insertion: ___/___/_____ Event Details *Specific Event:  Symptomatic UTI (SUTI)  Asymptomatic Bacteremic UTI (ABUTI) *Specify Criteria Used: (check all that apply) Signs & Symptoms  Fever: Single temperature  37.8C [>100F], or >37.2C [> 99F] on repeated occasions, or an increase of >1.1 o C (>2 o F) over baseline  Rigors  New onset hypotension  New onset confusion / functional decline  Acute pain, swelling, or tenderness of the testes, epididymis, or prostate  Acute dysuria  Purulent drainage at catheter insertion site New and/or marked increase in (check all that apply):  Urgency  Costovertebral angle pain or tenderness  Frequency  Suprapubic tenderness  Incontinence  Visible (gross) hematuria Laboratory & Diagnostic Testing  Positive culture with ≥10 5 CFU/ml with single predominant microorganism or 2 species of gram negative microorganisms from voided specimen  Positive culture with ≥10 2 CFU/ml of any microorganisms from in/out catheter specimen  Positive culture with ≥10 5 CFU/ml of any microorganisms from newly placed indwelling catheter specimen  Leukocytosis (>14,000 cells/mm 3 ), or Left shift (>6% or 1,500 bands/mm 3 )  Positive blood culture with 1 matching organism in urine culture Secondary Bloodstream Infection: Yes No *Transfer to acute care facility: Yes No If yes, date of transfer:___/___/_____ Died: Yes No UTI Contributed to Death: Yes No *Pathogens Identified: Yes No *If Yes, specify on pages 2-3. Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). Public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333, ATTN: PRA ( ). CDC (Front) v6.5

Urinary Tract Infection (UTI) for LTCF Page 2 of 4 Pathogen # Gram-positive Organisms _____ Staphylococcus coagulase-negative VANC S I R N _____ Enterococcus spp. (specify) __________ AMP S I R N CIPRO/LEVO/MOXI S I R N DAPTO S NS N DOXY/MINO S I R N GENTHL § S R N LNZ S I R N STREPHL § S R N TETRA S I R N TIG S NS N VANC S I R N _____ Enterococcus faecium AMP S I R N CIPRO/LEVO/MOXI S I R N DAPTO S NS N DOXY/MINO S I R N GENTHL § S R N LNZ S I R N QUIDAL S I R N STREPHL § S R N TETRA S I R N TIG S NS N VANC S I R N _____ Staphylococcus aureus CHLOR S I R N CIPRO/LEVO/MOXI S I R N CLIND S I R N DAPTO S NS N DOXY/MINO S I R N ERYTH S I R N GENT S I R N LNZ S R N OX/CEFOX/METH S I R N QUIDAL S I R N RIF S I R N TETRA S I R N TIG S NS N TMZ S I R N VANC S I R N Pathogen # Gram-negative Organisms _____ Acinetobacter spp. (specify) AMK S I R N AMPSUL S I R N AZT S I R N CEFEP S I R N CEFTAZ S I R N CIPRO/LEVO S I R N COL/PB S I R N GENT S I R N ___________ IMI S I R N MERO/DORI S I R N PIP/PIPTAZ S I R N TETRA/DOXY/MINO S I R N TMZ S I R N TOBRA S I R N _____ Escherichia coli AMK S I R N AMP S I R N AMPSUL/AMXCLV S I R N AZT S I R N CEFAZ S I R N CEFEP S I R N CEFOT/CEFTRX S I R N CEFTAZ S I R N CEFUR S I R N CEFOX/CETET S I R N CHLOR S I R N CIPRO/LEVO/MOXI S I R N COL/PB S I R N ERTA S I R N GENT S I R N IMI S I R N MERO/DORI S I R N PIPTAZ S I R N TETRA/DOXY/MINO S I R N TIG S I R N TMZ S I R N TOBRA S I R N _____ Enterobacter spp. (specify) AMK S I R N AMP S I R N AMPSUL/AMXCLV S I R N AZT S I R N CEFAZ S I R N CEFEP S I R N CEFOT/CEFTRX S I R N ___________ CEFTAZ S I R N CEFUR S I R N CEFOX/CETET S I R N CHLOR S I R N CIPRO/LEVO/MOXI S I R N COL/PB S I R N ERTA S I R N GENT S I R N IMI S I R N MERO/DORI S I R N PIPTAZ S I R N TETRA/DOXY/MINO S I R N TIG S I R N TMZ S I R N TOBRA S I R N _____ Klebsiella spp. (specify) AMK S I R N AMP S I R N AMPSUL/AMXCLV S I R N AZT S I R N CEFAZ S I R N CEFEP S I R N CEFOT/CEFTRX S I R N ___________ CEFTAZ S I R N CEFUR S I R N CEFOX/CETET S I R N CHLOR S I R N CIPRO/LEVO/MOXI S I R N COL/PB S I R N ERTA S I R N GENT S I R N IMI S I R N MERO/DORI S I R N PIPTAZ S I R N TETRA/DOXY/MINO S I R N TIG S I R N TMZ S I R N TOBRA S I R N CDC (Back) v6.5 (specify): _________________________ OMB No. xxxx-xxxx Exp. Date: xx-xx-xxxx

Pathogen # Fungal Organisms _____Candida spp. ( specify) __________________ ANID S NS N CASPO S NS N FLUCO S S-DD R N FLUCY S I R N ITRA S S-DD R N MICA S NS N VORI S S-DD R N Pathogen # Other Organisms _____ Organism 1 ( specify) __________________ ____ Drug 1 S I R N ____ Drug 2 S I R N ____ Drug 3 S I R N ____ Drug 4 S I R N ____ Drug 5 S I R N ____ Drug 6 S I R N ____ Drug 7 S I R N ____ Drug 8 S I R N ____ Drug 9 S I R N _____ Organism 2 (specify) __________________ ____ Drug 1 S I R N ____ Drug 2 S I R N ____ Drug 3 S I R N ____ Drug 4 S I R N ____ Drug 5 S I R N ____ Drug 6 S I R N ____ Drug 7 S I R N ____ Drug 8 S I R N ____ Drug 9 S I R N _____ Organism 3 (specify) __________________ ____ Drug 1 S I R N ____ Drug 2 S I R N ____ Drug 3 S I R N ____ Drug 4 S I R N ____ Drug 5 S I R N ____ Drug 6 S I R N ____ Drug 7 S I R N ____ Drug 8 S I R N ____ Drug 9 S I R N Drug Codes: AMK = amikacin AMP = ampicillin AMPSUL = ampicillin/sulbactam AMXCLV = amoxicillin/clavulanic acid ANID = anidulafungin AZT = aztreonam CASPO = caspofungin CEFAZ= cefazolin CEFEP = cefepime CEFOT = cefotaxime CEFOX= cefoxitin CEFTAZ = ceftazidime CEFTRX = ceftriaxone CEFUR= cefuroxime CETET= cefotetan CHLOR= chloramphenicol CIPRO = ciprofloxacin CLIND = clindamycin COL = colistin DAPTO = daptomycin DORI = doripenem DOXY = doxycycline ERTA = ertapenem ERYTH = erythromycin FLUCO = fluconazole FLUCY = flucytosine GENT = gentamicin GENTHL = gentamicin – high level test IMI = imipenem ITRA = itraconazole LEVO = levofloxacin LNZ = linezolid MERO = meropenem METH = methicillin MICA = micafungin MINO = minocycline MOXI = moxifloxacin OX = oxacillin PB = polymyxin B PIP = piperacillin PIPTAZ = piperacillin/tazobactam QUIDAL = quinupristin/dalfopristin RIF = rifampin STREPHL = streptomycin – high level test TETRA = tetracycline TICLAV = ticarcillin/clavulanic acid TIG = tigecycline TMZ = trimethoprim/sulfamethoxazole TOBRA = tobramycin VANC = vancomycin VORI = voriconazole Result Codes S = Susceptible I = Intermediate R = Resistant NS = Non-susceptible S-DD = Susceptible-dose dependent N = Not tested § GENTHL and STREPHL results: S=Susceptible/Synergistic and R=Resistant/Not Synergistic _____ Serratia marcescens AMK S I R N AMP S I R N AMPSUL/AMXCLV S I R N AZT S I R N CEFAZ S I R N CEFEP S I R N CEFOT/CEFTRX S I R N CEFTAZ S I R N CEFUR S I R N CEFOX/CETET S I R N CHLOR S I R N CIPRO/LEVO/MOXI S I R N COL/PB S I R N ERTA S I R N GENT S I R N IMI S I R N MERO/DORI S I R N PIPTAZ S I R N TETRA/DOXY/MINO S I R N TIG S I R N TMZ S I R N TOBRA S I R N _____ Pseudomonas aeruginosa AMK S I R N AZT S I R N CEFEP S I R N CEFTAZ S I R N CIPRO/LEVO S I R N COL/PB S I R N GENT S I R N IMI S I R N MERO/DORI S I R N PIP/PIPTAZ S I R N TOBRA S I R N _____ Stenotrophomonas maltophilia LEVO S I R N TETRA/MINO S I R N TICLAV S I R N TMZ S I R N Pathogen # Gram-negative Organisms (continued) Urinary Tract Infection (UTI) for LTCF Page 3 of 4 CDC (Back) v6.5 OMB No. xxxx-xxxx Exp. Date: xx-xx-xxxx

Custom Fields Label ________________________ ___/___/___ ________________________ ___________ Label ________________________ ___/___/___ ________________________ ___________ Comments Urinary Tract Infection (UTI) for LTCF Page 4 of 4 OMB No. xxxx-xxxx Exp. Date: xx-xx-xxxx CDC (Back) v6.5